Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Up 1.1% – Still a Buy?

Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) rose 1.1% on Monday . The stock traded as high as $96.32 and last traded at $95.97. Approximately 15,776 shares were traded during trading, an increase of 13% from the average session volume of 13,907 shares. The stock had previously closed at $94.91.

Invesco Biotechnology & Genome ETF Stock Performance

The business’s 50 day moving average price is $93.80 and its 200-day moving average price is $86.34. The firm has a market capitalization of $302.31 million, a PE ratio of 20.44 and a beta of 0.71.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Invesco Biotechnology & Genome ETF by 25.9% during the first quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock worth $4,698,000 after buying an additional 12,215 shares in the last quarter. Cetera Investment Advisers raised its holdings in Invesco Biotechnology & Genome ETF by 2.0% in the first quarter. Cetera Investment Advisers now owns 23,139 shares of the company’s stock valued at $1,832,000 after acquiring an additional 464 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Invesco Biotechnology & Genome ETF by 6.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,666 shares of the company’s stock worth $876,000 after acquiring an additional 666 shares during the last quarter. Archford Capital Strategies LLC lifted its stake in Invesco Biotechnology & Genome ETF by 6.7% in the second quarter. Archford Capital Strategies LLC now owns 6,252 shares of the company’s stock worth $560,000 after acquiring an additional 395 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its holdings in Invesco Biotechnology & Genome ETF by 7.0% during the 1st quarter. Kestra Advisory Services LLC now owns 6,280 shares of the company’s stock worth $497,000 after acquiring an additional 411 shares in the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.